CL2020002075A1 - Métodos para tratar el cáncer con anticuerpos anti-pd1. - Google Patents
Métodos para tratar el cáncer con anticuerpos anti-pd1.Info
- Publication number
- CL2020002075A1 CL2020002075A1 CL2020002075A CL2020002075A CL2020002075A1 CL 2020002075 A1 CL2020002075 A1 CL 2020002075A1 CL 2020002075 A CL2020002075 A CL 2020002075A CL 2020002075 A CL2020002075 A CL 2020002075A CL 2020002075 A1 CL2020002075 A1 CL 2020002075A1
- Authority
- CL
- Chile
- Prior art keywords
- antigen
- methods
- binding fragment
- treating cancer
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con métodos para tratar cáncer en un paciente que comprende administrar un antagonista de PD-1, por ejemplo, un anticuerpo de anti-PD-1 o un fragmento de unión a antígeno del mismo (por ejemplo, pembrolizumab), en cantidades específicas al paciente aproximadamente cada seis semanas. En algunas modalidades, la cantidad del anticuerpo de anti-PD-1 o un fragmento de unión a antígeno del mismo es aproximadamente 400 mg. En ciertas modalidades, el antagonista de PD-1 es pembrolizumab o un fragmento de unión a antígeno del mismo. También se proporcionan las composiciones y kits que comprenden una dosis de un anticuerpo de anti-PD-1 o un fragmento de unión a antígeno del mismo y los usos del mismo para tratar cáncer
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630038P | 2018-02-13 | 2018-02-13 | |
| US201862732828P | 2018-09-18 | 2018-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002075A1 true CL2020002075A1 (es) | 2020-10-23 |
Family
ID=67620026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002075A CL2020002075A1 (es) | 2018-02-13 | 2020-08-10 | Métodos para tratar el cáncer con anticuerpos anti-pd1. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12358984B2 (es) |
| EP (1) | EP3752180A4 (es) |
| JP (2) | JP2021513541A (es) |
| KR (1) | KR20200119844A (es) |
| CN (2) | CN120919306A (es) |
| AU (2) | AU2019220495B2 (es) |
| BR (1) | BR112020016331A8 (es) |
| CA (1) | CA3090995A1 (es) |
| CL (1) | CL2020002075A1 (es) |
| IL (1) | IL276303A (es) |
| MA (1) | MA52789A (es) |
| MX (2) | MX2020008445A (es) |
| SG (1) | SG11202007590TA (es) |
| WO (1) | WO2019160751A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| CN120053667A (zh) | 2019-03-25 | 2025-05-30 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
| EP4034163A4 (en) * | 2019-09-27 | 2023-11-08 | Merck Sharp & Dohme LLC | METHOD FOR TREATING METASTASIC TRIPLE NEGATIVE BREAST CANCER USING ANTI-PD-1 ANTIBODIES |
| US20230355757A1 (en) | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
| CA3162311A1 (en) * | 2019-12-20 | 2021-06-24 | Philip E. Brandish | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| CN112326961B (zh) * | 2020-10-30 | 2021-08-06 | 福州迈新生物技术开发有限公司 | 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备 |
| CN112394102B (zh) * | 2020-11-05 | 2023-05-26 | 上海交通大学医学院附属瑞金医院 | 一种检测垂体功能减退症的标志物及其应用 |
| WO2022268887A1 (en) | 2021-06-23 | 2022-12-29 | Formycon Ag | Formulations of anti-pd1 antibodies |
| US20250011453A1 (en) * | 2021-07-20 | 2025-01-09 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| CN113893343A (zh) * | 2021-10-16 | 2022-01-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗宫颈癌患者的药物中的用途 |
| WO2023114346A2 (en) * | 2021-12-16 | 2023-06-22 | Merck Sharp & Dohme Llc | Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy |
| JP2026501288A (ja) | 2022-12-21 | 2026-01-14 | フォーマイコン アーゲー | 抗ｐｄ１抗体の製剤 |
| CN115925954A (zh) * | 2022-12-28 | 2023-04-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途 |
| WO2025140467A1 (zh) * | 2023-12-29 | 2025-07-03 | 上海复宏汉霖生物技术股份有限公司 | 稳定的高浓度抗pd-1抗体药物制剂 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CA2352572C (en) | 1998-12-01 | 2010-04-20 | Abbvie Biotherapeutics Inc. | Humanized antibodies to gamma-interferon |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| JP5191537B2 (ja) * | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| CA2830806C (en) | 2011-03-31 | 2020-05-12 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| EP2981821B2 (en) | 2013-04-02 | 2021-11-03 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| CA2934028A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| KR20170052569A (ko) * | 2014-07-18 | 2017-05-12 | 어드박시스, 인크. | 전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용 |
| CA2955676A1 (en) * | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| US20170313775A1 (en) | 2014-11-13 | 2017-11-02 | The Johns Hopkins University | Checkpoint Blockade and Microsatellite Instability |
| AR103726A1 (es) * | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
| ES2861352T3 (es) * | 2015-04-28 | 2021-10-06 | Bristol Myers Squibb Co | Tratamiento del melanoma positivo para PD-L1 utilizando un anticuerpo anti-PD-1 |
| WO2016196389A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| US20190030023A1 (en) * | 2016-01-22 | 2019-01-31 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| KR102500659B1 (ko) | 2016-02-29 | 2023-02-16 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
| WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
| TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 |
| JP2019516767A (ja) | 2016-05-23 | 2019-06-20 | イーライ リリー アンド カンパニー | 癌の治療のためのペンブロリズマブとアベマシクリブとの組合せ |
| EP3464369A1 (en) | 2016-06-03 | 2019-04-10 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treating a tumor |
| LT3512547T (lt) | 2016-09-14 | 2021-01-11 | Abbvie Biotherapeutics Inc. | Antikūnai prieš pd-1 |
| BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
| WO2018223040A1 (en) * | 2017-06-01 | 2018-12-06 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-pd-1 antibody |
-
2019
- 2019-02-08 SG SG11202007590TA patent/SG11202007590TA/en unknown
- 2019-02-08 MA MA052789A patent/MA52789A/fr unknown
- 2019-02-08 US US16/966,968 patent/US12358984B2/en active Active
- 2019-02-08 CN CN202511206047.8A patent/CN120919306A/zh active Pending
- 2019-02-08 AU AU2019220495A patent/AU2019220495B2/en active Active
- 2019-02-08 BR BR112020016331A patent/BR112020016331A8/pt unknown
- 2019-02-08 JP JP2020542960A patent/JP2021513541A/ja active Pending
- 2019-02-08 CA CA3090995A patent/CA3090995A1/en active Pending
- 2019-02-08 MX MX2020008445A patent/MX2020008445A/es unknown
- 2019-02-08 WO PCT/US2019/017177 patent/WO2019160751A2/en not_active Ceased
- 2019-02-08 KR KR1020207026004A patent/KR20200119844A/ko not_active Ceased
- 2019-02-08 CN CN201980013286.8A patent/CN111712255A/zh active Pending
- 2019-02-08 EP EP19754909.0A patent/EP3752180A4/en active Pending
-
2020
- 2020-07-26 IL IL276303A patent/IL276303A/en unknown
- 2020-08-10 CL CL2020002075A patent/CL2020002075A1/es unknown
- 2020-08-12 MX MX2024013016A patent/MX2024013016A/es unknown
-
2023
- 2023-09-01 US US18/459,842 patent/US20240026003A1/en not_active Abandoned
-
2024
- 2024-01-04 JP JP2024000162A patent/JP2024038251A/ja active Pending
-
2026
- 2026-02-12 AU AU2026201041A patent/AU2026201041A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202007590TA (en) | 2020-09-29 |
| JP2024038251A (ja) | 2024-03-19 |
| MA52789A (fr) | 2021-04-14 |
| EP3752180A4 (en) | 2021-12-15 |
| AU2026201041A1 (en) | 2026-03-05 |
| BR112020016331A2 (pt) | 2020-12-15 |
| RU2020129827A (ru) | 2022-03-14 |
| US20240026003A1 (en) | 2024-01-25 |
| KR20200119844A (ko) | 2020-10-20 |
| AU2019220495A1 (en) | 2020-08-13 |
| JP2021513541A (ja) | 2021-05-27 |
| BR112020016331A8 (pt) | 2023-02-07 |
| US12358984B2 (en) | 2025-07-15 |
| AU2019220495B2 (en) | 2025-11-13 |
| WO2019160751A3 (en) | 2020-09-10 |
| IL276303A (en) | 2020-09-30 |
| US20210047408A1 (en) | 2021-02-18 |
| CA3090995A1 (en) | 2019-08-22 |
| CN111712255A (zh) | 2020-09-25 |
| CN120919306A (zh) | 2025-11-11 |
| EP3752180A2 (en) | 2020-12-23 |
| MX2020008445A (es) | 2020-09-28 |
| WO2019160751A2 (en) | 2019-08-22 |
| MX2024013016A (es) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| MX2024007358A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
| CR20190162A (es) | Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| MX2020010913A (es) | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| CO2021008665A2 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| MX2022001065A (es) | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. | |
| CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
| ECSP23076276A (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| CL2025003511A1 (es) | Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1. | |
| CR20220127A (es) | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 | |
| CO2021014370A2 (es) | Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen | |
| MX2023015070A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo. | |
| AR110620A1 (es) | Terapias combinadas de receptores de antígeno quiméricos e inhibidores de pd-1 | |
| DOP2025000008A (es) | Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma | |
| MX2022005245A (es) | Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer. | |
| AR130745A1 (es) | Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| MX2022006883A (es) | Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario. | |
| PE20250161A1 (es) | Dosis para tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3 en pacientes mayores |